Are the Derived Indexes of Peripheral Whole Blood Cell Counts (NLR, PLR, LMR/MLR) Clinically Significant Prognostic Biomarkers in Multiple Myeloma? A Systematic Review And Meta-Analysis

Multiple myeloma (MM) is an incurable malignant plasma cell tumor. Whole blood cell count (WBCC) derived indexes are widely used as a predictive biomarker for various types of solid and hematological malignant tumors. Our study is to evaluate its effectiveness in MM by meta-analysis. Relevant litera...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 11; p. 766672
Main Authors Zhang, Xinwen, Duan, Jialin, Wen, Zhenyu, Xiong, Hao, Chen, Xiaomin, Liu, Yang, Liao, Kunyu, Huang, Chunlan
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 23.11.2021
Subjects
lymphocyte-to-monocyte ratio (LMR)
monocyte-to-lymphocyte ratio (MLR)
multiple myeloma (MM)
neutrophil-to-lymphocyte ratio (NLR)
Oncology
platelet-to-lymphocyte ratio (PLR)
prognosis
lymphocyte-to-monocyte ratio (LMR)
platelet-to-lymphocyte ratio (PLR)
meta-analysis
neutrophil-to-lymphocyte ratio (NLR)
monocyte-to-lymphocyte ratio (MLR)
multiple myeloma (MM)
prognosis
Online AccessGet full text

Cover

Abstract Multiple myeloma (MM) is an incurable malignant plasma cell tumor. Whole blood cell count (WBCC) derived indexes are widely used as a predictive biomarker for various types of solid and hematological malignant tumors. Our study is to evaluate its effectiveness in MM by meta-analysis. Relevant literatures were retrieved from PubMed, Embase and Web of Science databases according to PRISMA guideline. All relevant parameters were extracted and combined for statistical analysis. Nineteen studies incorporating 3818 MM patients were eventually included in this meta-analysis. 13 studies evaluated that elevated NLR was significantly associated with poor survival outcomes (OS: HR=2.04, <0.001; PFS: HR=1.96, =0.003). Elevated NLR was revealed to correlate with ISS stage (ISS III VS I-II, OR=2.23, =0.003). A total of 7 studies have shown that elevated LMR predicts a better prognosis in MM patients (OS: HR=0.57, <0.001; PFS: HR=0.49, <0.05), and two other studies demonstrated that increased MLR was related to poor OS/PFS (OS: HR=1.58, <0.05; PFS: HR=1.60, <0.05). However, in the other 6 studies including 1560 patients, the prognostic value of PLR had not been confirmed (OS: HR=0.89, >0.05; PFS: HR=0.87, >0.05). The indexes NLR and LMR/MLR derived from WBCC were validated to be useful biomarkers to predict the prognosis in MM patients, but the evidence of PLR was insufficient.
AbstractList BackgroundMultiple myeloma (MM) is an incurable malignant plasma cell tumor. Whole blood cell count (WBCC) derived indexes are widely used as a predictive biomarker for various types of solid and hematological malignant tumors. Our study is to evaluate its effectiveness in MM by meta-analysis.MethodsRelevant literatures were retrieved from PubMed, Embase and Web of Science databases according to PRISMA guideline. All relevant parameters were extracted and combined for statistical analysis.ResultsNineteen studies incorporating 3818 MM patients were eventually included in this meta-analysis. 13 studies evaluated that elevated NLR was significantly associated with poor survival outcomes (OS: HR=2.04, P<0.001; PFS: HR=1.96, P=0.003). Elevated NLR was revealed to correlate with ISS stage (ISS III VS I-II, OR=2.23, P=0.003). A total of 7 studies have shown that elevated LMR predicts a better prognosis in MM patients (OS: HR=0.57, P<0.001; PFS: HR=0.49, P<0.05), and two other studies demonstrated that increased MLR was related to poor OS/PFS (OS: HR=1.58, P<0.05; PFS: HR=1.60, P<0.05). However, in the other 6 studies including 1560 patients, the prognostic value of PLR had not been confirmed (OS: HR=0.89, P>0.05; PFS: HR=0.87, P>0.05).ConclusionsThe indexes NLR and LMR/MLR derived from WBCC were validated to be useful biomarkers to predict the prognosis in MM patients, but the evidence of PLR was insufficient.
Background Multiple myeloma (MM) is an incurable malignant plasma cell tumor. Whole blood cell count (WBCC) derived indexes are widely used as a predictive biomarker for various types of solid and hematological malignant tumors. Our study is to evaluate its effectiveness in MM by meta-analysis. Methods Relevant literatures were retrieved from PubMed, Embase and Web of Science databases according to PRISMA guideline. All relevant parameters were extracted and combined for statistical analysis. Results Nineteen studies incorporating 3818 MM patients were eventually included in this meta-analysis. 13 studies evaluated that elevated NLR was significantly associated with poor survival outcomes (OS: HR=2.04, P <0.001; PFS: HR=1.96, P =0.003). Elevated NLR was revealed to correlate with ISS stage (ISS III VS I-II, OR=2.23, P =0.003). A total of 7 studies have shown that elevated LMR predicts a better prognosis in MM patients (OS: HR=0.57, P <0.001; PFS: HR=0.49, P <0.05), and two other studies demonstrated that increased MLR was related to poor OS/PFS (OS: HR=1.58, P <0.05; PFS: HR=1.60, P <0.05). However, in the other 6 studies including 1560 patients, the prognostic value of PLR had not been confirmed (OS: HR=0.89, P >0.05; PFS: HR=0.87, P >0.05). Conclusions The indexes NLR and LMR/MLR derived from WBCC were validated to be useful biomarkers to predict the prognosis in MM patients, but the evidence of PLR was insufficient.
BACKGROUNDMultiple myeloma (MM) is an incurable malignant plasma cell tumor. Whole blood cell count (WBCC) derived indexes are widely used as a predictive biomarker for various types of solid and hematological malignant tumors. Our study is to evaluate its effectiveness in MM by meta-analysis. METHODSRelevant literatures were retrieved from PubMed, Embase and Web of Science databases according to PRISMA guideline. All relevant parameters were extracted and combined for statistical analysis. RESULTSNineteen studies incorporating 3818 MM patients were eventually included in this meta-analysis. 13 studies evaluated that elevated NLR was significantly associated with poor survival outcomes (OS: HR=2.04, P<0.001; PFS: HR=1.96, P=0.003). Elevated NLR was revealed to correlate with ISS stage (ISS III VS I-II, OR=2.23, P=0.003). A total of 7 studies have shown that elevated LMR predicts a better prognosis in MM patients (OS: HR=0.57, P<0.001; PFS: HR=0.49, P<0.05), and two other studies demonstrated that increased MLR was related to poor OS/PFS (OS: HR=1.58, P<0.05; PFS: HR=1.60, P<0.05). However, in the other 6 studies including 1560 patients, the prognostic value of PLR had not been confirmed (OS: HR=0.89, P>0.05; PFS: HR=0.87, P>0.05). CONCLUSIONSThe indexes NLR and LMR/MLR derived from WBCC were validated to be useful biomarkers to predict the prognosis in MM patients, but the evidence of PLR was insufficient.
Multiple myeloma (MM) is an incurable malignant plasma cell tumor. Whole blood cell count (WBCC) derived indexes are widely used as a predictive biomarker for various types of solid and hematological malignant tumors. Our study is to evaluate its effectiveness in MM by meta-analysis. Relevant literatures were retrieved from PubMed, Embase and Web of Science databases according to PRISMA guideline. All relevant parameters were extracted and combined for statistical analysis. Nineteen studies incorporating 3818 MM patients were eventually included in this meta-analysis. 13 studies evaluated that elevated NLR was significantly associated with poor survival outcomes (OS: HR=2.04, <0.001; PFS: HR=1.96, =0.003). Elevated NLR was revealed to correlate with ISS stage (ISS III VS I-II, OR=2.23, =0.003). A total of 7 studies have shown that elevated LMR predicts a better prognosis in MM patients (OS: HR=0.57, <0.001; PFS: HR=0.49, <0.05), and two other studies demonstrated that increased MLR was related to poor OS/PFS (OS: HR=1.58, <0.05; PFS: HR=1.60, <0.05). However, in the other 6 studies including 1560 patients, the prognostic value of PLR had not been confirmed (OS: HR=0.89, >0.05; PFS: HR=0.87, >0.05). The indexes NLR and LMR/MLR derived from WBCC were validated to be useful biomarkers to predict the prognosis in MM patients, but the evidence of PLR was insufficient.
Author Huang, Chunlan
Chen, Xiaomin
Xiong, Hao
Wen, Zhenyu
Zhang, Xinwen
Liao, Kunyu
Duan, Jialin
Liu, Yang
AuthorAffiliation 1 Stem Cell Laboratory, Affiliated Hospital of Southwest Medical University , Luzhou , China
2 Department of Hematology, Affiliated Hospital of Southwest Medical University , Luzhou , China
3 Department of Orthopedics, Affiliated Hospital of Southwest Medical University , Luzhou , China
AuthorAffiliation_xml – name: 2 Department of Hematology, Affiliated Hospital of Southwest Medical University , Luzhou , China
– name: 3 Department of Orthopedics, Affiliated Hospital of Southwest Medical University , Luzhou , China
– name: 1 Stem Cell Laboratory, Affiliated Hospital of Southwest Medical University , Luzhou , China
Author_xml – sequence: 1
  givenname: Xinwen
  surname: Zhang
  fullname: Zhang, Xinwen
  organization: Department of Hematology, Affiliated Hospital of Southwest Medical University, Luzhou, China
– sequence: 2
  givenname: Jialin
  surname: Duan
  fullname: Duan, Jialin
  organization: Department of Hematology, Affiliated Hospital of Southwest Medical University, Luzhou, China
– sequence: 3
  givenname: Zhenyu
  surname: Wen
  fullname: Wen, Zhenyu
  organization: Department of Orthopedics, Affiliated Hospital of Southwest Medical University, Luzhou, China
– sequence: 4
  givenname: Hao
  surname: Xiong
  fullname: Xiong, Hao
  organization: Department of Hematology, Affiliated Hospital of Southwest Medical University, Luzhou, China
– sequence: 5
  givenname: Xiaomin
  surname: Chen
  fullname: Chen, Xiaomin
  organization: Department of Hematology, Affiliated Hospital of Southwest Medical University, Luzhou, China
– sequence: 6
  givenname: Yang
  surname: Liu
  fullname: Liu, Yang
  organization: Department of Hematology, Affiliated Hospital of Southwest Medical University, Luzhou, China
– sequence: 7
  givenname: Kunyu
  surname: Liao
  fullname: Liao, Kunyu
  organization: Department of Hematology, Affiliated Hospital of Southwest Medical University, Luzhou, China
– sequence: 8
  givenname: Chunlan
  surname: Huang
  fullname: Huang, Chunlan
  organization: Department of Hematology, Affiliated Hospital of Southwest Medical University, Luzhou, China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34888244$$D View this record in MEDLINE/PubMed
BookMark eNpVkktvEzEQx1eoiJbSOyfkY5FI6vVrvRdQGl6REqhSENwsr3c2cXHsYG8C-Wh8OxxSqtYHezyPn0ee_9PiyAcPRfG8xENKZX3RBW-GBJNyWAkhKvKoOCGEskHN6Peje_ZxcZbSDc5LcFxi-qQ4pkxKSRg7Kf6MIqB-CegtRLuFFk18C78hodChq-xaLyFqh74tgwN06UJo0RicQ-Ow8X1C55-m81foar9NZ_OL2XT-Eo2d9dZo53bo2i687fLF9-gqhoUPqbcGXdqw0vEHxISsR7ON6-0642c7cDnwBo3Q9S71sNL75DlsLfxCI9-iGfR6MPLa7ZJNz4rHnXYJzm7P0-Lr-3dfxh8H088fJuPRdGCYIP1AVgyLllPoWq2l4IbgVnSyLEVHDGVGayp1x5iuBCWyZpWucMtow3hTVy0l9LSYHLht0DdqHW1ufaeCtuqfI8SF0jE36kABGFFjw0nTNKwTuOG1YTxTu1IDB8is1wfWetOsoDXg-_y7D6API94u1SJsldyPjlcZcH4LiOHnBlKvVjaZPBDtIWySIgJLTjlnMqfiQ6qJIaUI3d0zJVZ7Aam9gNReQOogoFzy4n57dwX_5UL_AvRMxWA
CitedBy_id crossref_primary_10_1080_16078454_2023_2210929
crossref_primary_10_3892_wasj_2022_165
crossref_primary_10_3389_fpubh_2022_960740
crossref_primary_10_2147_JIR_S433424
crossref_primary_10_2217_fon_2022_0523
crossref_primary_10_1080_16078454_2023_2240145
Cites_doi 10.1056/NEJMoa1402888
10.1111/bjh.15141
10.1016/j.ctrv.2014.02.005
10.12659/MSM.923716
10.1136/bmj.315.7109.629
10.21037/tcr.2018.01.13
10.1634/theoncologist.2012-0034
10.1002/ajh.24883
10.1186/1471-2288-11-139
10.2147/CMAR.S227671
10.1038/sj.leu.2404413
10.1111/j.1538-7836.2010.04131.x
10.1186/1745-6215-8-16
10.1158/1078-0432.CCR-17-2003
10.1038/s41408-017-0019-6
10.1160/TH13-08-0632
10.1007/s00277-013-1978-8
10.3109/09537104.2013.805405
10.1182/blood-2015-05-643320
10.1200/JCO.2005.04.242
10.1172/JCI37223
10.1159/000445045
10.1016/j.cct.2015.09.002
10.1182/blood-2007-10-119123
10.1017/s0266462305050154
10.2147/OTT.S52501
10.1002/path.1027
10.1111/ctr.13359
10.1002/jcla.22107
10.1038/leu.2013.313
10.1136/bmj.327.7414.557
10.3324/haematol.2011.056176
10.1182/blood-2009-10-246660
10.2307/2533446
10.3389/fonc.2021.707742
10.1002/ajh.23810
10.1038/leu.2008.336
10.3978/j.issn.2072-1439.2013.12.34
10.1371/journal.pone.0006713
10.1182/blood-2006-08-040410
10.1002/ajh.24402
10.3390/cancers12040921
10.1182/blood-2006-04-015909
10.1002/jcla.22032
10.2217/fon.09.136
10.1038/bcj.2017.60
10.18632/oncotarget.13320
10.1038/s41409-019-0681-3
10.1186/s12935-018-0609-9
10.1016/j.critrevonc.2018.09.016
10.1056/NEJMoa043445
10.1097/MD.0000000000007051
10.1186/1471-2288-14-45
10.1016/j.leukres.2014.07.005
10.1155/2018/9434637
10.1007/BF02573067
10.1182/blood-2005-07-2817
10.1016/S1470-2045(14)70442-5
10.4132/KoreanJPathol.2013.47.6.526
10.1002/jcla.22004
10.1038/leu.2008.259
10.3904/kjim.2016.054
10.1016/j.ccr.2009.08.019
10.1097/MD.0000000000012678
10.1007/s00277-012-1652-6
10.1007/s00277-020-04092-5
10.1002/ijc.30060
10.3233/CBM-170795
10.1182/blood-2005-04-1411
10.2147/OTT.S153146
ContentType Journal Article
Copyright Copyright © 2021 Zhang, Duan, Wen, Xiong, Chen, Liu, Liao and Huang.
Copyright © 2021 Zhang, Duan, Wen, Xiong, Chen, Liu, Liao and Huang 2021 Zhang, Duan, Wen, Xiong, Chen, Liu, Liao and Huang
Copyright_xml – notice: Copyright © 2021 Zhang, Duan, Wen, Xiong, Chen, Liu, Liao and Huang.
– notice: Copyright © 2021 Zhang, Duan, Wen, Xiong, Chen, Liu, Liao and Huang 2021 Zhang, Duan, Wen, Xiong, Chen, Liu, Liao and Huang
DBID NPM
AAYXX
CITATION
7X8
5PM
DOA
DOI 10.3389/fonc.2021.766672
DatabaseName PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList
CrossRef
MEDLINE - Academic
PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2234-943X
EndPage 766672
ExternalDocumentID oai_doaj_org_article_eec690c52bbb4f60b59c45289f1ae5ee
10_3389_fonc_2021_766672
34888244
Genre Systematic Review
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
DIK
EBS
EJD
EMOBN
GROUPED_DOAJ
GX1
HYE
IAO
IEA
IHR
IHW
IPNFZ
KQ8
M48
M~E
NPM
OK1
PGMZT
RIG
RNS
RPM
AAYXX
CITATION
7X8
5PM
ID FETCH-LOGICAL-c462t-87406d53efdaa865c20d6f8116f2c34caa38af44a76328947a70d43b45b97d323
IEDL.DBID RPM
ISSN 2234-943X
IngestDate Tue Oct 22 15:15:40 EDT 2024
Tue Sep 17 21:27:56 EDT 2024
Fri Oct 25 08:02:17 EDT 2024
Thu Sep 26 19:28:32 EDT 2024
Sat Sep 28 08:20:59 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords lymphocyte-to-monocyte ratio (LMR)
platelet-to-lymphocyte ratio (PLR)
meta-analysis
neutrophil-to-lymphocyte ratio (NLR)
monocyte-to-lymphocyte ratio (MLR)
multiple myeloma (MM)
prognosis
Language English
License Copyright © 2021 Zhang, Duan, Wen, Xiong, Chen, Liu, Liao and Huang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c462t-87406d53efdaa865c20d6f8116f2c34caa38af44a76328947a70d43b45b97d323
Notes content type line 23
SourceType-Scholarly Journals-1
Edited by: Claudio Cerchione, Istituto Scientifico Romagnolo per lo Studio e il Trattamento dei Tumori (IRCCS), Italy
These authors share first authorship
Reviewed by: Rehan Khan, Case Western Reserve University, United States; İsmail Burak Atalay, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Turkey
This article was submitted to Hematologic Malignancies, a section of the journal Frontiers in Oncology
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650157/
PMID 34888244
PQID 2608535548
PQPubID 23479
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_eec690c52bbb4f60b59c45289f1ae5ee
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8650157
proquest_miscellaneous_2608535548
crossref_primary_10_3389_fonc_2021_766672
pubmed_primary_34888244
PublicationCentury 2000
PublicationDate 2021-11-23
PublicationDateYYYYMMDD 2021-11-23
PublicationDate_xml – month: 11
  year: 2021
  text: 2021-11-23
  day: 23
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in oncology
PublicationTitleAlternate Front Oncol
PublicationYear 2021
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Szudy-Szczyrek (B30) 2020; 99
Suyanı (B60) 2013; 92
Baranyai (B69) 2014; 111
Bambace (B65) 2011; 9
Zuo (B34) 2018; 7
Vincent (B1) 2014; 89
Green (B59) 2009; 4
Shin (B47) 2013; 47
Bingle (B61) 2002; 196
Ikeda (B64) 2002; 9
Dolan (B18) 2018; 132
Wu (B63) 2017; 96
Wongrakpanich (B44) 2016; 30
Dosani (B43) 2017; 7
Richardson (B7) 2006; 108
Lakshman (B9) 2017; 92
DerSimonian (B26) 2015; 45
Shah (B10) 2015; 126
Higgins (B25) 2003; 327
Zhang (B45) 2016; 9
Koh (B62) 2012; 17
Lemancewicz (B70) 2013; 25
Jakubowiak (B8) 2014; 40
Li (B41) 2017; 31
Zeng (B53) 2018; 97
Chauhan (B52) 2009; 16
Onec (B40) 2017; 31
Salman (B68) 2016; 61
Gertz (B16) 2005; 106
Rajkumar (B20) 2014; 15
Greipp (B12) 2005; 23
Shi (B38) 2017; 8
Richardson (B5) 2005; 352
Gutierrez (B15) 2007; 21
Xu (B50) 2021; 11
Xiong (B13) 2008; 112
Michiels (B22) 2005; 21
Sweiss (B33) 2020; 55
Liu (B67) 2013; 6
Ross (B17) 2012; 97
Roxburgh (B19) 2010; 6
Zhao (B49) 2016; 139
Mu (B51) 2018; 18
Begg (B27) 1994; 50
Palumbo (B11) 2014; 371
Yang (B31) 2020; 26
Takagi (B71) 2018; 24
Kim (B42) 2017; 32
Roodman (B3) 2009; 23
Podar (B48) 2009; 23
Lo (B21) 2014; 14
Liu (B32) 2019; 11
Solmaz (B36) 2018; 32
Witte (B29) 2020; 12
Avet-Loiseau (B14) 2007; 109
Mu (B54) 2018; 11
Jablonska (B58) 2010; 120
Li (B56) 2014; 38
Tian (B37) 2018; 2018
Egger (B28) 1997; 315
Zhou (B35) 2018; 22
Kumar (B4) 2014; 28
Rajkumar (B6) 2005; 106
Hoyle (B24) 2011; 11
Rajkumar (B2) 2016; 91
Tierney (B23) 2007; 8
Romano (B39) 2017; 7
Beltran (B55) 2018; 184
Prabhala (B57) 2010; 115
Liu (B66) 2013; 5
Kelkitli (B46) 2014; 93
References_xml – volume: 371
  start-page: 895
  year: 2014
  ident: B11
  article-title: Autologous Transplantation and Maintenance Therapy in Multiple Myeloma
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1402888
  contributor:
    fullname: Palumbo
– volume: 9
  year: 2016
  ident: B45
  article-title: Peripheral Blood Lymphocyte to Monocyte Ratio Predicts Outcome in Newly-Diagnosed Multiple Myeloma Patients With Extramedullary Involvements
  publication-title: Int J Clin Exp Med
  contributor:
    fullname: Zhang
– volume: 184
  year: 2018
  ident: B55
  article-title: The Neutrophil-Lymphocyte Ratio is Prognostic in Patients With Early Stage Aggressive Peripheral T Cell Lymphoma
  publication-title: Brit J Haematol
  doi: 10.1111/bjh.15141
  contributor:
    fullname: Beltran
– volume: 40
  year: 2014
  ident: B8
  article-title: Evolution of Carfilzomib Dose and Schedule in Patients With Multiple Myeloma: A Historical Overview
  publication-title: Cancer Treat Rev
  doi: 10.1016/j.ctrv.2014.02.005
  contributor:
    fullname: Jakubowiak
– volume: 26
  start-page: e923716
  year: 2020
  ident: B31
  article-title: Peripheral Absolute Lymphocyte Count: An Economical and Clinical Available Immune-Related Prognostic Marker for Newly Diagnosed Multiple Myeloma
  publication-title: Med Sci Monit
  doi: 10.12659/MSM.923716
  contributor:
    fullname: Yang
– volume: 315
  year: 1997
  ident: B28
  article-title: Bias in Meta-Analysis Detected by a Simple, Graphical Test
  publication-title: BMJ
  doi: 10.1136/bmj.315.7109.629
  contributor:
    fullname: Egger
– volume: 7
  start-page: 88
  year: 2018
  ident: B34
  article-title: Prognostic Significance of Neutrophil-Lymphocyte Ratio in Multiple Myeloma Patients
  publication-title: T ransl Cancer Res
  doi: 10.21037/tcr.2018.01.13
  contributor:
    fullname: Zuo
– volume: 17
  year: 2012
  ident: B62
  article-title: The Ratio of the Absolute Lymphocyte Count to the Absolute Monocyte Count Is Associated With Prognosis in Hodgkin’s Lymphoma: Correlation With Tumor-Associated Macrophages
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2012-0034
  contributor:
    fullname: Koh
– volume: 92
  year: 2017
  ident: B9
  article-title: Efficacy of Daratumumab-Based Therapies in Patients With Relapsed, Refractory Multiple Myeloma Treated Outside of Clinical Trials
  publication-title: Am J Hematol
  doi: 10.1002/ajh.24883
  contributor:
    fullname: Lakshman
– volume: 11
  year: 2011
  ident: B24
  article-title: Improved Curve Fits to Summary Survival Data: Application to Economic Evaluation of Health Technologies
  publication-title: BMC Med Res Methodol
  doi: 10.1186/1471-2288-11-139
  contributor:
    fullname: Hoyle
– volume: 11
  year: 2019
  ident: B32
  article-title: Prognostic Significance of The Inflammatory Index-Based Scoring System In Patients Preliminarily Diagnosed With Multiple Myeloma In The Bortezomib-Based Chemotherapy Era
  publication-title: Cancer Manag Res
  doi: 10.2147/CMAR.S227671
  contributor:
    fullname: Liu
– volume: 21
  year: 2007
  ident: B15
  article-title: Prognostic and Biological Implications of Genetic Abnormalities in Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: T (
  publication-title: Leukemia
  doi: 10.1038/sj.leu.2404413
  contributor:
    fullname: Gutierrez
– volume: 9
  year: 2011
  ident: B65
  article-title: The Platelet Contribution to Cancer Progression
  publication-title: J Thromb Haemost
  doi: 10.1111/j.1538-7836.2010.04131.x
  contributor:
    fullname: Bambace
– volume: 8
  year: 2007
  ident: B23
  article-title: Practical Methods for Incorporating Summary Time-to-Event Data Into Meta-Analysis
  publication-title: Trials
  doi: 10.1186/1745-6215-8-16
  contributor:
    fullname: Tierney
– volume: 24
  year: 2018
  ident: B71
  article-title: Platelets Enhance Multiple Myeloma Progression via IL-1β Upregulation
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-17-2003
  contributor:
    fullname: Takagi
– volume: 7
  start-page: 649
  year: 2017
  ident: B39
  article-title: The NLR and LMR Ratio in Newly Diagnosed MM Patients Treated Upfront With Novel Agents
  publication-title: Blood Cancer J
  doi: 10.1038/s41408-017-0019-6
  contributor:
    fullname: Romano
– volume: 111
  start-page: 483–90
  year: 2014
  ident: B69
  article-title: The Comparison of Thrombocytosis and Platelet-Lymphocyte Ratio as Potential Prognostic Markers in Colorectal Cancer
  publication-title: Thromb Haemostasis
  doi: 10.1160/TH13-08-0632
  contributor:
    fullname: Baranyai
– volume: 93
  year: 2014
  ident: B46
  article-title: Predicting Survival for Multiple Myeloma Patients Using Baseline Neutrophil/Lymphocyte Ratio
  publication-title: Ann Hematol
  doi: 10.1007/s00277-013-1978-8
  contributor:
    fullname: Kelkitli
– volume: 25
  year: 2013
  ident: B70
  article-title: Bone Marrow Megakaryocytes, Soluble P-Selectin and Thrombopoietic Cytokines in Multiple Myeloma Patients
  publication-title: Platelets
  doi: 10.3109/09537104.2013.805405
  contributor:
    fullname: Lemancewicz
– volume: 126
  year: 2015
  ident: B10
  article-title: Carfilzomib, Pomalidomide, and Dexamethasone for Relapsed or Refractory Myeloma
  publication-title: Blood
  doi: 10.1182/blood-2015-05-643320
  contributor:
    fullname: Shah
– volume: 23
  year: 2005
  ident: B12
  article-title: International Staging System for Multiple Myeloma
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2005.04.242
  contributor:
    fullname: Greipp
– volume: 120
  year: 2010
  ident: B58
  article-title: Neutrophils Responsive to Endogenous IFN-β Regulate Tumor Angiogenesis and Growth in a Mouse Tumor Model
  publication-title: J Clin Invest
  doi: 10.1172/JCI37223
  contributor:
    fullname: Jablonska
– volume: 61
  year: 2016
  ident: B68
  article-title: Prognostic Value of the Pretreatment Neutrophil-To-Lymphocyte Ratio and Platelet-To-Lymphocyte Ratio for Patients With Neuroendocrine Tumors: An Izmir Oncology Group Study
  publication-title: Chemotherapy
  doi: 10.1159/000445045
  contributor:
    fullname: Salman
– volume: 45
  year: 2015
  ident: B26
  article-title: Meta-Analysis in Clinical Trials Revisited
  publication-title: Contemp Clin Trials
  doi: 10.1016/j.cct.2015.09.002
  contributor:
    fullname: DerSimonian
– volume: 112
  year: 2008
  ident: B13
  article-title: An Analysis of the Clinical and Biologic Significance of TP53 Loss and the Identification of Potential Novel Transcriptional Targets of TP53 in Multiple Myeloma
  publication-title: Blood
  doi: 10.1182/blood-2007-10-119123
  contributor:
    fullname: Xiong
– volume: 21
  year: 2005
  ident: B22
  article-title: Meta-Analysis When Only the Median Survival Times are Known: A Comparison With Individual Patient Data Results
  publication-title: Int J Technol Assess Health Care
  doi: 10.1017/s0266462305050154
  contributor:
    fullname: Michiels
– volume: 6
  year: 2013
  ident: B67
  article-title: Combination of Neutrophil Lymphocyte Ratio and Platelet Lymphocyte Ratio is a Useful Predictor of Postoperative Survival in Patients With Esophageal Squamous Cell Carcinoma
  publication-title: Onco Targets Ther
  doi: 10.2147/OTT.S52501
  contributor:
    fullname: Liu
– volume: 196
  year: 2002
  ident: B61
  article-title: The Role of Tumour-Associated Macrophages in Tumour Progression: Implications for New Anticancer Therapies
  publication-title: J Pathol
  doi: 10.1002/path.1027
  contributor:
    fullname: Bingle
– volume: 32
  start-page: e13359
  year: 2018
  ident: B36
  article-title: Can Neutrophil-To-Lymphocyte Ratio, Monocyte-To-Lymphocyte Ratio, and Platelet-To-Lymphocyte Ratio at Day +100 be Used as a Prognostic Marker in Multiple Myeloma Patients With Autologous Transplantation
  publication-title: Clin Transplant
  doi: 10.1111/ctr.13359
  contributor:
    fullname: Solmaz
– volume: 31
  start-page: e22107
  year: 2017
  ident: B41
  article-title: Pretreatment Neutrophil/Lymphocyte Ratio But Not Platelet/Lymphocyte Ratio has a Prognostic Impact in Multiple Myeloma
  publication-title: J Clin Lab Anal
  doi: 10.1002/jcla.22107
  contributor:
    fullname: Li
– volume: 28
  year: 2014
  ident: B4
  article-title: Continued Improvement in Survival in Multiple Myeloma: Changes in Early Mortality and Outcomes in Older Patients
  publication-title: Leukemia
  doi: 10.1038/leu.2013.313
  contributor:
    fullname: Kumar
– volume: 327
  year: 2003
  ident: B25
  article-title: Measuring Inconsistency in Meta-Analyses
  publication-title: BMJ
  doi: 10.1136/bmj.327.7414.557
  contributor:
    fullname: Higgins
– volume: 97
  year: 2012
  ident: B17
  article-title: Report From the European Myeloma Network on Interphase FISH in Multiple Myeloma and Related Disorders
  publication-title: Haematologica
  doi: 10.3324/haematol.2011.056176
  contributor:
    fullname: Ross
– volume: 115
  year: 2010
  ident: B57
  article-title: Elevated IL-17 Produced by Th17 Cells Promotes Myeloma Cell Growth and Inhibits Immune Function in Multiple Myeloma
  publication-title: Blood
  doi: 10.1182/blood-2009-10-246660
  contributor:
    fullname: Prabhala
– volume: 50
  year: 1994
  ident: B27
  article-title: Operating Characteristics of a Rank Correlation Test for Publication Bias
  publication-title: Biometrics
  doi: 10.2307/2533446
  contributor:
    fullname: Begg
– volume: 11
  year: 2021
  ident: B50
  article-title: Prognostic Value of Peripheral Whole Blood Cell Counts Derived Indexes in Gallbladder Carcinoma: A Systematic Review and Meta-Analysis
  publication-title: Front Oncol
  doi: 10.3389/fonc.2021.707742
  contributor:
    fullname: Xu
– volume: 89
  start-page: 999
  year: 2014
  ident: B1
  article-title: Multiple Myeloma: 2014 Update on Diagnosis, Risk-Stratification, and Management
  publication-title: Am J Hematol
  doi: 10.1002/ajh.23810
  contributor:
    fullname: Vincent
– volume: 23
  year: 2009
  ident: B3
  article-title: Pathogenesis of Myeloma Bone Disease
  publication-title: Leukemia
  doi: 10.1038/leu.2008.336
  contributor:
    fullname: Roodman
– volume: 5
  year: 2013
  ident: B66
  article-title: Pretreatment Platelet-to-Lymphocyte Ratio (PLR) as a Predictor of Response to First-Line Platinum-Based Chemotherapy and Prognosis for Patients With non-Small Cell Lung Cancer
  publication-title: J Thorac Dis
  doi: 10.3978/j.issn.2072-1439.2013.12.34
  contributor:
    fullname: Liu
– volume: 4
  start-page: e6713
  year: 2009
  ident: B59
  article-title: Chemoattractant Signaling Between Tumor Cells and Macrophages Regulates Cancer Cell Migration, Metastasis and Neovascularization
  publication-title: PloS One
  doi: 10.1371/journal.pone.0006713
  contributor:
    fullname: Green
– volume: 109
  year: 2007
  ident: B14
  article-title: Genetic Abnormalities and Survival in Multiple Myeloma: The Experience of the Intergroupe Francophone Du Myelome
  publication-title: Blood
  doi: 10.1182/blood-2006-08-040410
  contributor:
    fullname: Avet-Loiseau
– volume: 91
  year: 2016
  ident: B2
  article-title: Multiple Myeloma: 2016 Update on Diagnosis, Risk-Stratification, and Management
  publication-title: Am J Hematol
  doi: 10.1002/ajh.24402
  contributor:
    fullname: Rajkumar
– volume: 12
  start-page: 921
  year: 2020
  ident: B29
  article-title: The Glasgow Prognostic Score at Diagnosis Is a Predictor of Clinical Outcome in Patients With Multiple Myeloma Undergoing Autologous Haematopoietic Stem Cell Transplantation
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers12040921
  contributor:
    fullname: Witte
– volume: 108
  year: 2006
  ident: B7
  article-title: A Randomized Phase 2 Study of Lenalidomide Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
  publication-title: Blood
  doi: 10.1182/blood-2006-04-015909
  contributor:
    fullname: Richardson
– volume: 31
  start-page: e22032
  year: 2017
  ident: B40
  article-title: The Predictive Role of the Neutrophil/Lymphocyte Ratio in Survival With Multiple Myeloma: A Single Center Experience
  publication-title: J Clin Lab Anal
  doi: 10.1002/jcla.22032
  contributor:
    fullname: Onec
– volume: 6
  year: 2010
  ident: B19
  article-title: Role of Systemic Inflammatory Response in Predicting Survival in Patients With Primary Operable Cancer
  publication-title: Future Oncol
  doi: 10.2217/fon.09.136
  contributor:
    fullname: Roxburgh
– volume: 7
  start-page: e579
  year: 2017
  ident: B43
  article-title: Significance of the Absolute Lymphocyte/Monocyte Ratio as a Prognostic Immune Biomarker in Newly Diagnosed Multiple Myeloma
  publication-title: Blood Cancer J
  doi: 10.1038/bcj.2017.60
  contributor:
    fullname: Dosani
– volume: 8
  year: 2017
  ident: B38
  article-title: Elevated Neutrophil-to-Lymphocyte Ratio and Monocyte-to-Lymphocyte Ratio and Decreased Platelet-to-Lymphocyte Ratio are Associated With Poor Prognosis in Multiple Myeloma
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.13320
  contributor:
    fullname: Shi
– volume: 55
  start-page: 199
  year: 2020
  ident: B33
  article-title: Combined Immune Score of Lymphocyte to Monocyte Ratio and Immunoglobulin Levels Predicts Treatment-Free Survival of Multiple Myeloma Patients After Autologous Stem Cell Transplant
  publication-title: Bone Marrow Transplant
  doi: 10.1038/s41409-019-0681-3
  contributor:
    fullname: Sweiss
– volume: 18
  start-page: 119
  year: 2018
  ident: B51
  article-title: Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Diffuse Large B Cell Lymphoma Patients: An Updated Dose–Response Meta-Analysis
  publication-title: Cancer Cell Int
  doi: 10.1186/s12935-018-0609-9
  contributor:
    fullname: Mu
– volume: 132
  year: 2018
  ident: B18
  article-title: The Prognostic Value of the Systemic Inflammatory Response in Randomised Clinical Trials in Cancer: A Systematic Review
  publication-title: Crit Rev Oncol Hematol
  doi: 10.1016/j.critrevonc.2018.09.016
  contributor:
    fullname: Dolan
– volume: 352
  year: 2005
  ident: B5
  article-title: Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa043445
  contributor:
    fullname: Richardson
– volume: 96
  start-page: e7051
  year: 2017
  ident: B63
  article-title: Prognostic Role of the Lymphocyte-to-Monocyte Ratio in Colorectal Cancer
  publication-title: Medicine
  doi: 10.1097/MD.0000000000007051
  contributor:
    fullname: Wu
– volume: 14
  year: 2014
  ident: B21
  article-title: Newcastle-Ottawa Scale: Comparing Reviewers’ to Authors’ Assessments
  publication-title: BMC Med Res Methodol
  doi: 10.1186/1471-2288-14-45
  contributor:
    fullname: Lo
– volume: 38
  year: 2014
  ident: B56
  article-title: Potential Relationship and Clinical Significance of miRNAs and Th17 Cytokines in Patients With Multiple Myeloma
  publication-title: Leukemia Res
  doi: 10.1016/j.leukres.2014.07.005
  contributor:
    fullname: Li
– volume: 2018
  year: 2018
  ident: B37
  article-title: Peripheral Blood Lymphocyte-To-Monocyte Ratio as a Useful Prognostic Factor in Newly Diagnosed Multiple Myeloma
  publication-title: BioMed Res Int
  doi: 10.1155/2018/9434637
  contributor:
    fullname: Tian
– volume: 9
  year: 2002
  ident: B64
  article-title: Poor Prognosis Associated With Thrombocytosis in Patients With Gastric Cancer
  publication-title: Ann Surg Oncol
  doi: 10.1007/BF02573067
  contributor:
    fullname: Ikeda
– volume: 106
  year: 2005
  ident: B6
  article-title: Combination Therapy With Lenalidomide Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma
  publication-title: Blood
  doi: 10.1182/blood-2005-07-2817
  contributor:
    fullname: Rajkumar
– volume: 15
  year: 2014
  ident: B20
  article-title: International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(14)70442-5
  contributor:
    fullname: Rajkumar
– volume: 47
  year: 2013
  ident: B47
  article-title: Prognostic Significance of Absolute Lymphocyte Count/Absolute Monocyte Count Ratio at Diagnosis in Patients With Multiple Myeloma
  publication-title: Korean J Pathol
  doi: 10.4132/KoreanJPathol.2013.47.6.526
  contributor:
    fullname: Shin
– volume: 30
  year: 2016
  ident: B44
  article-title: The Prognostic Significance of Neutrophil-To-Lymphocyte and Platelet-To-Lymphocyte Ratios in Patients With Multiple Myeloma
  publication-title: J Clin Lab Anal
  doi: 10.1002/jcla.22004
  contributor:
    fullname: Wongrakpanich
– volume: 23
  start-page: 10
  year: 2009
  ident: B48
  article-title: Bone Marrow Microenvironment and the Identification of New Targets for Myeloma Therapy
  publication-title: Leukemia
  doi: 10.1038/leu.2008.259
  contributor:
    fullname: Podar
– volume: 32
  year: 2017
  ident: B42
  article-title: Myeloma Prognostic Index at Diagnosis Might be a Prognostic Marker in Patients Newly Diagnosed With Multiple Myeloma
  publication-title: Korean J Intern Med
  doi: 10.3904/kjim.2016.054
  contributor:
    fullname: Kim
– volume: 16
  year: 2009
  ident: B52
  article-title: Functional Interaction of Plasmacytoid Dendritic Cells With Multiple Myeloma Cells: A Therapeutic Target
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2009.08.019
  contributor:
    fullname: Chauhan
– volume: 97
  start-page: e12678
  year: 2018
  ident: B53
  article-title: Prognostic Value of Neutrophil to Lymphocyte Ratio and Clinicopathological Characteristics for Multiple Myeloma
  publication-title: Medicine
  doi: 10.1097/MD.0000000000012678
  contributor:
    fullname: Zeng
– volume: 92
  year: 2013
  ident: B60
  article-title: Tumor-Associated Macrophages as a Prognostic Parameter in Multiple Myeloma
  publication-title: Ann Hematol
  doi: 10.1007/s00277-012-1652-6
  contributor:
    fullname: Suyanı
– volume: 99
  year: 2020
  ident: B30
  article-title: Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Multiple Myeloma Patients Treated With Thalidomide-Based Regimen
  publication-title: Ann Hematol
  doi: 10.1007/s00277-020-04092-5
  contributor:
    fullname: Szudy-Szczyrek
– volume: 139
  year: 2016
  ident: B49
  article-title: Prognostic Role of Platelet to Lymphocyte Ratio in Non-Small Cell Lung Cancers: A Meta-Analysis Including 3,720 Patients
  publication-title: Int J Cancer
  doi: 10.1002/ijc.30060
  contributor:
    fullname: Zhao
– volume: 22
  year: 2018
  ident: B35
  article-title: Evaluation of Neutrophil-to-Lymphocyte Ratio in Newly Diagnosed Patients Receiving Borte- Zomib-Based Therapy for Multiple Myeloma
  publication-title: Cancer biomark
  doi: 10.3233/CBM-170795
  contributor:
    fullname: Zhou
– volume: 106
  year: 2005
  ident: B16
  article-title: (P16.3;Q32), and -17p13 in Myeloma Patients Treated With High-Dose Therapy
  publication-title: Blood
  doi: 10.1182/blood-2005-04-1411
  contributor:
    fullname: Gertz
– volume: 11
  start-page: 499
  year: 2018
  ident: B54
  article-title: Prognostic Role of Neutrophil-Lymphocyte Ratio in Multiple Myeloma: A Dose-Response Meta-Analysis
  publication-title: Onco Targets Ther
  doi: 10.2147/OTT.S153146
  contributor:
    fullname: Mu
SSID ssj0000650103
Score 2.3579879
SecondaryResourceType review_article
Snippet Multiple myeloma (MM) is an incurable malignant plasma cell tumor. Whole blood cell count (WBCC) derived indexes are widely used as a predictive biomarker for...
Background Multiple myeloma (MM) is an incurable malignant plasma cell tumor. Whole blood cell count (WBCC) derived indexes are widely used as a predictive...
BACKGROUNDMultiple myeloma (MM) is an incurable malignant plasma cell tumor. Whole blood cell count (WBCC) derived indexes are widely used as a predictive...
BackgroundMultiple myeloma (MM) is an incurable malignant plasma cell tumor. Whole blood cell count (WBCC) derived indexes are widely used as a predictive...
SourceID doaj
pubmedcentral
proquest
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 766672
SubjectTerms lymphocyte-to-monocyte ratio (LMR)
monocyte-to-lymphocyte ratio (MLR)
multiple myeloma (MM)
neutrophil-to-lymphocyte ratio (NLR)
Oncology
platelet-to-lymphocyte ratio (PLR)
prognosis
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Ni9RAEG1kD-JFXD_jqpTgwQXjZNIfSU4ys7qsMlmGWRf3FrqTig7ERGaywv40_51VSWaYEcGLlxy6Q9L0q-5-RVW_EuIVyiKPizD2S4OBT_w29l3CgDhl0EqXWMn3ndNzc3apPl3pq51SX5wT1ssD9xM3QszJgct16JxTpQmcTnKlyU0oxxY1Yrf7BsmOM9XvwZoLGPRxSfLCklHZ1KxYGI7fRsTYo3DvHOrk-v_GMf9Mldw5e07vibsDaYRJP9hDcQvr--J2OoTFH4hfkxUCMTl4T_b0Ewv4yBqIuIamhDk1ddIBFXzhWrgw5VR1OMGqAr6Q3q7h9fls8Qbm_Jili1E6WxzDoBdaVTdwsfxac0IRYQDzVcOZeTQOmC6b75zbs1rDsoZ0SEyE9AYr6ngHE7jYqkRDH4KASV1Aiq31N1ooD8Xl6YfPJ2f-UJPBz5UJW58r-JlCSywLa2Oj8zAoTBmPx6YMc6lya2VsS6Us7VsEkopsFBRKOqVdEhUylI_EQd3U-ESAI2gTk9B3ZKDyhKhmiIbczVJp1OToeOJ4g1D2o5feyMhlYTQzRjNjNLMeTU9MGcLteyya3TWQKWWDKWX_MiVPvNwYQEaLjCMntsbmep2R00e0hphX7InHvUFsfyVpC4yJJHki2jOVvbHs99TLb52Qd8xWqqOn_2PwR-IOzwdfkwzlM3HQrq7xOfGl1r3olsZvfcsWRQ
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELbQIiEuiDflpUHiwEpkN40fSQ5o1S6sFtSsqi4Ve4vsZLJbKSSQdhH9afw7Zpq0UNQjlxzsJLb8je1v5PE3QrxGmWdRHkReYdD3iN9GnosZEKcMWuliK_m-c3JmTqfq04W--HM9uhvA-U7XjvNJTZvy4Of35RFN-HfscdJ-e1jUFYsRBv2DkMh4SAvyzUCRn86BfB3Zb9dlzUkN2rPKnR9u7U0rCf9dvPPf8Mm_9qOTu-JORyRh0CJ_T9zA6r64lXRH5Q_Er0GDQOwO3pON_cAcPrIuIs6hLmBMRSs5gRK-cH5cGHL4OhxjWQJfUl_M4c3ZaPIWxvwYJZPDZDTZh05DtCyXcD67rDjIiHCBcVNztB71A4az-ivH-zRzmFWQdMGKkCyxpIojGMD5Rjka2mMJGFQ5JLiw3lof5aGYnnz4fHzqdXkavEyZYOFxVj-Ta4lFbm1kdBb4uSmift8UQSZVZq2MbKGUpbWM_DsV2tDPlXRKuzjMZSAfib2qrvCJAIeYxSam_0hfZTHRzwANuaCF0qjJ-emJ_TVC6bdWjiMlN4bRTBnNlNFMWzR7YsgQbt5jIe1VQd1cpt28TKk9E_uZDpxzqjC-03GmNPWy6FvUiD3xam0AKU08Pk2xFdbX85QcQaI6xMainnjcGsSmKUnLYkTEqSfCLVPZ6st2TTW7Wol7R2ylOnz6Pzr_TNzm8eCrk4F8LvYWzTW-IA61cC9XU-M3Er4dlA
  priority: 102
  providerName: Scholars Portal
Title Are the Derived Indexes of Peripheral Whole Blood Cell Counts (NLR, PLR, LMR/MLR) Clinically Significant Prognostic Biomarkers in Multiple Myeloma? A Systematic Review And Meta-Analysis
URI https://www.ncbi.nlm.nih.gov/pubmed/34888244
https://search.proquest.com/docview/2608535548
https://pubmed.ncbi.nlm.nih.gov/PMC8650157
https://doaj.org/article/eec690c52bbb4f60b59c45289f1ae5ee
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtNAFB21XSA2iDfmUV0kFlTCie0Zj-0VSgKloLiKUiqys2bG4xLJsaskReqn8Xfc60fUIFZsZuHnyPfYc67nzLmMvbM8N3EexG4hreciv41dnVBAtJBWcZ0oTuud03N5dim-LcLFAQv7tTCNaN_o5aAqV4Nq-bPRVl6vzLDXiQ1n6SRGWuFjJn_IDhGgd1L09vMbUu2CdkoSE7BkWNQVmRUG_iBCsh5RARuOuI1xZNsbjRrT_n8xzb8Fk3dGoNOH7EFHHWHUdvERO7DVY3Yv7SbHn7Dfo7UF5HPwCVH1y-bwlZwQ7QbqAma4qTEQKOEHVcSFMQnWYWLLEmhZ-nYD78-n8w8wo2aazofpdH4CnWtoWd7CxfKqIlkRRgJm65r0edgPGC_rFSl81htYVpB28kRIb22JOz7CCC52XtHQTkTAqMohtVvl9o4oT9nl6efvkzO3q8zgGiGDrUt1_GQeclvkSmE0TODlsoh9XxaB4cIoxWNVCKHw64UZnYhU5OWCaxHqJMp5wJ-xo6qu7AsG2lqTyASvwz1hEiScgZWYdBYitCGmOw476SOUXbcGHBkmLhTYjAKbUWCzNrAOG1MId8eRdXazoV5fZR2AMryfTDwTBlprUUhPh4kRIfay8JUNrXXY2x4AGb5qNH-iKlvfbDJM_ZDcIP-KHfa8BcTuVj2gHBbtQWWvL_t7EN2NnXeH5pf_feYrdp8eAq2QDPhrdrRd39g3SJW2-rj5xYDtl4WPbSri4-Zl-QO-gRg9
link.rule.ids 230,315,730,783,787,867,888,2109,24330,27936,27937,53804,53806
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jj9MwGLWGQQIu7EtZPyQOjETaNF6SnFBbGHWgqarZmFtkO85QkSajNkUa_hn_js9ZqumIC1xyiLM49nP8Pvn5fYS8MzTRQeIFTiqM6yC_DRwV2g5RTBhJVSip3e8cTcX4hH0542c7hLd7YSrRvlbzbp4tuvn8e6WtvFjoXqsT682iUYC0oo-R_A1yE8ery64E6fUPmNvsBfWiJIZgYS8tcmtX6PW7PtJ136awoYjcAOe2rfmosu3_G9e8Lpm8Mgft3yOnbe1r6cmP7rpUXf3rmrHjP3_efXK3YaUwqIsfkB2TPyS3ombd_RH5PVgaQKoInxCwP00CB9Zk0aygSGGGpypvggy-2WS7MLRaeBiZLAO7471cwfvp5PADzOxhEh32osnhHjSGpFl2CUfz89wqlrCTYbYsrPQP6wHDebGw4qHlCuY5RI3yEaJLk2HBRxjA0caGGuo1DhjkCUSmlE5rtvKYnOx_Ph6NnSbpg6OZ8ErHpggUCacmTaTEltCem4g06PdF6mnKtJQ0kCljEn-MGCwyX_puwqhiXIV-Qj36hOzmRW6eEVDG6FCE-BzqMh0il_WMwHg2ZdxwjKQ6ZK_t-vii9vaIMSayiIktYmKLmLhGTIcMLTY211lX7upEsTyPm86L8X0idDX3lFIsFa7ioWYca5n2peHGdMjbFlkxjmK7NCNzU6xXMUaVyJuQ2gUd8rRG2uZVLVI7xN_C4FZdtksQWZVTeIOk5_995xtye3wcTeLJwfTrC3LHNojdiOnRl2S3XK7NK2RkpXpdjb8_6WA3cw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LjtMwFLVgkEZseD_K8yKxYCSSprHjJCvUdqhmoKmqDiNGbCLbcYaKNKnaFGn4M_6O6zyqdsRqNlk4L8c-js-Vj88l5L2miQoSN7BSrh0L-W1gydB0iGRcCypDQc1-52jCT87ZlwvvYifVVyXaV3Ju59nCzuc_K23lcqG6rU6sO42GAdKKHkbyyyTt3iZ3cMw6fCdQr3_CnslgUC9MYhgWdtMiN5aFbs_2kbL7Jo0NRfQGOL_tzUmVdf__-OZ12eTOPDS6T360X1DLT37Zm1La6s81c8cbfeIDcq9hp9CvL3lIbun8ETmMmvX3x-Rvf6UBKSMcI3B_6wROjdmiXkORwhSLKo-CDL6bpLswMJp4GOosA7PzvVzDh8l49hGm5jCOZt1oPDuCxpg0y67gbH6ZG-USdjZMV4WRAGI9YDAvFkZEtFrDPIeoUUBCdKUzPPEJ-nC2taOGeq0D-nkCkS6F1ZquPCHno8_fhidWk_zBUoy7pWVSBfLEozpNhMDWUK6T8DTo9XjqKsqUEDQQKWMCf5AYNDJf-E7CqGSeDP2EuvQpOciLXD8nILVWIQ_xOdRhKkRO62qOcW3KPO1hRNUhR233x8va4yPG2MigJjaoiQ1q4ho1HTIw-NheZ9y5q4JidRk3HRjj-3joKM-VUrKUO9ILFfOwlmlPaE_rDnnXoivG0WyWaESui806xugS-RNSvKBDntVo276qRWuH-Hs43KvL_hlEV-UY3qDpxY3vfEsOp8ejeHw6-fqS3DXtYfZjuvQVOShXG_0aiVkp31RD8B-Rfznz
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Are+the+Derived+Indexes+of+Peripheral+Whole+Blood+Cell+Counts+%28NLR%2C+PLR%2C+LMR%2FMLR%29+Clinically+Significant+Prognostic+Biomarkers+in+Multiple+Myeloma%3F+A+Systematic+Review+And+Meta-Analysis&rft.jtitle=Frontiers+in+oncology&rft.au=Xinwen+Zhang&rft.au=Xinwen+Zhang&rft.au=Jialin+Duan&rft.au=Jialin+Duan&rft.date=2021-11-23&rft.pub=Frontiers+Media+S.A&rft.eissn=2234-943X&rft.volume=11&rft_id=info:doi/10.3389%2Ffonc.2021.766672&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_eec690c52bbb4f60b59c45289f1ae5ee
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2234-943X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2234-943X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2234-943X&client=summon